ARQT vs PVLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARQT Captures Institutional Edge (2โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arcutis Biotherapeutics, Inc. Common Stock (ARQT) driven by superior Valuation, Growth & Margin while PVLA counters with relative strength in Momentum & Technical. Fundamentally, ARQT trades at 25.8x Forward P/E with 6.9% operating margin (+45.1% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ARQT sits in CONSOLIDATION (7th %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARQT Revenue | PVLA Revenue | ARQT Op. Margin | PVLA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $30M | N/A | -113.1% | PVLA |
| FY2019 | N/A | $40M | N/A | -62.2% | PVLA |
| FY2020 | N/A | $30M | N/A | -115.7% | PVLA |
| FY2021 | N/A | $30M | N/A | -165.0% | PVLA |
| FY2022 | $0M | $30M | -8183.0% | -167.8% | PVLA |
| FY2023 | $60M | $40M | -404.5% | -27.7% | PVLA |
| FY2024 | $200M | N/A | -65.3% | N/A | ARQT |
| FY2025 | $380M | N/A | -3.3% | N/A | ARQT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARQT | PVLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.5B | $2.2B | Larger Scale | ARQT |
| Trailing P/E Ratio Valuation | 125.1x | N/M | Lower Multiple | ARQT |
| Forward P/E Ratio Valuation | 25.8x | N/M | Lower Multiple | ARQT |
| Revenue Growth (YoY) Growth | +45.1% | +0.0% | Higher Growth | ARQT |
| Operating Margin (TTM) Profitability | 6.9% | 0.0% | Higher Margin | ARQT |
| Net Profit Margin Profitability | 5.9% | 0.0% | Higher Margin | ARQT |
| Return on Equity (ROE) Capital Efficiency | 14.9% | -63.4% | Higher ROE | ARQT |
| 52-Week Range Position Momentum | 51% ($19โ$35) | 68% ($72โ$180) | Stronger Trend | PVLA |
| Beta / 30D Volatility Risk Regime | 1.76ฮฒ ยท 87% Vol | 1.66ฮฒ ยท 75% Vol | Lower Realized Risk | PVLA |
| Unified Institutional Score Composite Signal | 62.5 / 100 (BUY) | 48.2 / 100 (HOLD) | Higher Composite | ARQT |